Introduction {#s0010}
============

Bovine respiratory disease (BRD) is one of the most commonly diagnosed causes of morbidity and mortality in cattle, both within large feedlots and traditional, smaller, pasture-based husbandry systems ([@bib0135], [@bib0390]). The pathogenesis of BRD is often driven by complex interactions of factors associated with the animal, the pathogen and the environment which creates significant challenges in its control ([@bib0135]).

The traditional model of primary viral infection followed by secondary bacterial opportunism has increasingly been challenged as being overly simplistic in failing to acknowledge the primary role of some pathogens that were previously considered of minor importance. The use of approaches in pathogen identification such as metagenomics has revealed the presence of some of these pathogens in bovine lungs which were rarely, or not previously, detected ([@bib0405]). Emerging knowledge of a potential role for these 'minor' players (e.g. bovine coronavirus, bovine rhinitis A virus) in the pathogenesis of BRD coupled with the polymicrobial nature of many cases, and the detection of many recognised BRD pathogens in the nasopharynx or lungs of healthy cattle ([@bib0060]), complicates BRD diagnosis and blurs the precise role played by specific pathogens in eliciting disease ([@bib0550], [@bib0390]). Determining the likely significance of detection of these pathogens in diseased bovine lungs is important in interpreting pathologic analyses, and in initiating control measures, for the veterinary practitioner and veterinary pathologist alike.

This review appraises the role of key pathogens implicated in BRD pathogenesis. These pathogens have been selected on the basis of a traditional assumption of their lesser importance in BRD pathogenesis; an assumption which has been called into question by recent evidence.

Histophilus somni {#s0020}
=================

*Histophilus somni* (formerly *Haemophilus somnus*) is a non-encapsulated gram negative bacterium associated with a number of clinical syndromes, including respiratory disease, in cattle maintained in feedlot ([@bib0180]) and traditional, smaller, pasture-based husbandry systems ([@bib0390]). *H. somni* pneumonia is not distinguishable clinically from other causes of BRD ([@bib0025]). Gross post-mortem findings in pneumonic animals include fibrinosuppurative bronchopneumonia often in conjunction with severe diffuse fibrinous pleuritis, although pleuritis can also occur as a solitary lesion ([@bib0485], [@bib0020]). Histologically, purulent bronchiolitis, vasculitis, fibrin thrombi and haemorrhage are typically recorded in acute cases ([@bib0020]).

The prevalence of *H. somni* detection post-mortem in pneumonic bovine lungs can vary considerably, with up to 40% recorded in some years ([@bib0560], [@bib0390]). *H. somni* strains differ in their ability to induce pneumonia in calves ([@bib0215]), may be found commensally in the genital ([@bib0325]) and respiratory tract, and can persist in the lung for long periods in the absence of clinical disease ([@bib0205]). Although a nasal prevalence of 42% has been recorded in beef cattle prior to export ([@bib0385]), once established it appears that *H. somni* survives more readily in the bronchoalveolar area than on the nasal mucosa ([@bib0205]). Following introduction into appropriate sites under favourable conditions, individual strains can change from being a commensal to either opportunistic pathogens or primary pathogens ([@bib0470]). In respiratory disease cases, *H. somni* can be found alone or in concert with other respiratory pathogens ([@bib0085], [@bib0390]). Synergism between *H. somni* and bovine respiratory syncytial virus (BRSV; [@bib0190]) has previously been reported. Interestingly, the order of infection appears to be critical with prior *H. somni* infection up-regulating the antiviral response of respiratory epithelial cells. This effect was mediated by lipooligosaccharide in a dose-dependent manner. This surprising result has raised the hope that nasal inoculation of at-risk cattle with isolates of *H. somni* from other subclinical carriers may, in the future, play a role in decreasing susceptibility to respiratory disease in a similar manner to that of gut probiotics such as *Lactobacillus acidophilus* ([@bib0340]).

While a role for *H. somni* in BRD has been long recognised ([@bib0200]), emerging awareness of the virulence factors which aid its pathogenesis has highlighted the potential importance of that role. *H. somni* can adhere to endothelial cells causing the activation of platelets which promotes thrombus formation while lipooligosaccharide production can induce apoptosis of endothelial cells ([@bib0520], [@bib0320]) and help the pathogen to evade host defences through phase variation ([@bib0285]). Immunoglobulin binding proteins (Ibps), which are secreted from the surface of the pathogen, bind the Fc region of IgG2b ([@bib0040]) and may also facilitate bacterial dissemination from the lungs across the alveolar barrier; [@bib0010] proposed a mechanism for dissemination which was mediated by retraction of alveolar type 2 cells, in response to Ibp A, and degradation of the basement membrane.

Biofilm formation by *H. somni* has also been recognised in vitro in both commensal and pathogenic strains. Bacterial biofilms are highly structured and organised aggregates of bacteria connected by an extracellular matrix which enable bacteria to colonise and persist in sites, enhancing their resistance to antibiotics and host defence mechanisms. As there are substantial differences in the amount and architecture of biofilm formed by commensal and pathogenic strains it has been suggested that the differences in biofilm structure may correlate with pathogenicity ([@bib0475]). Polymicrobial biofilms of commensal *H. somni* and *Pasteurella multocida* have been described ([@bib0150]). Transferring-binding proteins, which allow *H. somni* acquire iron from host components ([@bib0140]), histamine release, which causes vasoconstriction and increased permeability ([@bib0465]), and the resistance to killing by phagocytes ([@bib0510]), also contribute to *H. somni* survival. This latter attribute, together with its ability to destroy macrophages within hours in vivo ([@bib0200]), has led to the suggestion by [@bib0085] that *H. somni* behaves more like an extracellular parasite than a facultative intracellular parasite which multiplies over time inside macrophages. Animal defence against *H. somni* appears to rely on antibody responses, particularly IgG~2~ ([@bib0205], [@bib0090]), however, IgE responses are also sometimes induced and were suggested by [@bib0190] to have a role in the pathogenesis of the more severe BRD in some animals. In studies using Western blotting, [@bib0095] demonstrated that the predominant *H. somni* antigen recognised by IgE was major outer membrane protein (MOMP), a virulence factor of *H. somni*, the precise functional role of which is still uncertain, but a role similar to bacterial porins has been proposed ([@bib0540]).

[@bib0430] outlined three approaches to *H. somni* control in cattle: mass medication with antimicrobials, vaccination for *H. somni* or vaccination for other agents of the BRD complex that predispose to BRD. Mass medication with antimicrobials is discussed in detail in Part 2 of this review ([@bib0390]). Relevant to mass medication is the challenge potentially posed by an apparent trend of decreasing susceptibility of *H. somni* and other BRD pathogens to most of the antimicrobials used for the treatment and control of BRD ([@bib0130]). Antimicrobial resistance in BRD pathogens, including *H. somni*, mediated by plasmids and other integrative and conjugative elements (ICE) was evaluated by [@bib0315] in a study of isolates from US feedlots. Four of 10 *H. somni* lung isolates harboured multi-resistant genes. They demonstrated the presence of ICE in *H. somni* and the capacity for transfer of ICE from *H. somni* to *P. multocida*. Although plasmids have not been frequently isolated from *H. somni*, 15% of *H. somni* isolates from pneumonic lungs in one study in Denmark contained plasmids ([@bib0175]). In contrast, no plasmids were observed in any of 606 nasal isolates of *H. somni* from randomly selected healthy animals in a feedlot study by [@bib0120]. This led them to suggest that strains having plasmids may have virulence genes although this has not yet been proven. [@bib0450] recorded a decrease in the proportion of susceptible *H. somni* isolates, over a 10-year period from 2000 to 2009, which was most notable with enrofloxacin, florfenicol and tetracycline. Their report, which examined isolates from both sick and deceased animals, suggested that *H. somni* resistance was relatively low. This apparent divergence from the findings of [@bib0315] may be, in part, due to selection bias towards resistant pathogens in studies based on samples from BRD fatalities.

Although vaccination against *H. somni* is widely practised in the U.S. the efficacy of *H. somni* vaccination is uncertain or unproven ([@bib0330], [@bib0430]). Most *H. somni* vaccines use killed cells or specific outer membrane proteins to induce immunity. Research to identify new, and effective, vaccine epitopes continues with some encouraging results. [@bib0185] reported significantly reduced gross and microscopic lung lesion scores in calves inoculated twice with the Ibp A direct repeat (DR) 2 subunit following experimental inoculation with pathogenic *H. somni* strain 2336. This subunit also induced lower IgE antigen-specific responses than Ibp A3 and Ibp A5, which were also assessed. The findings of [@bib0350] also suggested that Ibp A DR2 would be a useful addition to *H. somni* vaccines.

An additional challenge in controlling *H. somni-*induced BRD is the identification of clinically infected animals; however, recent developments in this area are particularly noteworthy. Exopolysaccharide (EPS) is a major component of the *H. somni* biofilm matrix and is most abundantly produced when a biofilm is formed but is also produced under growth-restricting stress conditions which are likely to occur during the disease process or during colonisation of mucosal epithelia ([@bib0480], [@bib9010]). As EPS antigen is expressed predominantly during active disease, [@bib9010] have recently used purified EPS in a direct ELISA to differentiate animals (both naturally and experimentally infected) with *H. somni* disease from healthy commensally infected animals; sensitivity of 90.5% and specificity of 92.5% were reported 3 weeks post infection. [@bib0350] have also recently reported on IbpA subunit antigens which could potentially be deployed in a similar manner.

In conclusion, *H. somni* is now recognised as a significant BRD pathogen of relatively high prevalence which poses many challenges to the implementation of effective BRD control measures. Recent research addressing the diagnostic challenges in the live animal is likely to be of benefit in future BRD control, however, further research addressing the efficacy of vaccination is required.

Pasteurella multocida {#s0025}
=====================

*P. multocida* is a gram-negative coccobacillus, classified into five capsular serogroups (A, B, D, E, F; [@bib0050], [@bib0055]) and 16 serotypes ([@bib0265]). It has been isolated from many different species, is potentially zoonotic ([@bib0375]) and has been implicated in a number of different diseases, including BRD. *P. multocida* isolates from serogroup A may exist as either commensals or pathogens in the bovine respiratory tract and A: 3 is most commonly isolated from respiratory disease with a smaller isolation rate for D: 3 ([@bib0225], [@bib0500]). Gross post-mortem findings in animals with *P. multocida* pneumonia are typically described as acute bronchopneumonia characterised by well-demarcated deep red consolidation with an anteroventral distribution. Abscessation can occur which is potentially responsible for poor antimicrobial efficacy and may act as a source for recrudescence of infection. Histological lesions in acute cases typically include the infiltration of neutrophils into the alveolar and bronchiolar air spaces and extensive yet scattered areas of alveolar oedema. Fibrin may be abundant in the alveoli with occasional multinucleate giant cells also visible in the alveolar space ([@bib0115]). Although considered highly infectious, *P. multocida* is not considered to be highly contagious ([@bib0525]).

Reported respiratory prevalence of *P. multocida* in various published studies varies considerably due to differences in the disease status, age and enterprise type of the study animals, the sample type harvested, and the testing method employed. [@bib0030], using bacteriological culture of tracheobronchial lavage samples of dairy calves aged less than 3 months, isolated *P. multocida* from approximately 42% of diseased calves and 26% of healthy calves; [@bib0275] recorded 17% prevalence in nasal swabs of healthy beef calves aged less than 10 weeks using polymerase chain reaction (PCR), while [@bib0390] in a post-mortem survey of weanlings, both dairy and beef, between 6 and 12 months of age identified *P. multocida* in 37.9% of lungs with lesions and 14.3% of those without, using a combination of bacteriological culture and PCR. [@bib0560] reported an apparent increasing prevalence of *P. multocida* in a survey of lungs examined post-mortem over 8 years although the findings of [@bib0370] did not support this.

Co-infections of *P. multocida* with other respiratory pathogens in diseased animals are commonly recorded ([@bib0030], [@bib0390]). Synergism with *Mycoplasma bovis* has been proposed ([@bib0550]) and frequent detection of *P. multocida* with *Mycoplasma*-like organisms or bovine parainfluenza virus-3 has been reported ([@bib0275], [@bib0390]).

There has been some debate regarding the ability of *P. multocida* to assume a primary role in BRD pathogenesis. The plausibility of such a role is supported by the discovery of several virulence factors which help it to evade host defences including outer membrane proteins (e.g. OmpA) and type IV fimbriae which may be responsible for adherence to host cells ([@bib0195], [@bib0110]), lipopolysaccharide (LPS) which plays a role in the disease process by interacting with innate host immune defences through toll-like receptors ([@bib0230]), and a capsule which plays a role in resisting phagocytosis by host cells and complement-mediated lysis ([@bib0220]). Biofilm can be formed by *P. multocida*, and polymicrobial biofilms with *H. somni* are also reported ([@bib0150]). *P. multocida*, in common with other gram-negative bacteria, possesses outer membrane vesicles containing virulence factors such as toxins, enzymes (including β-lactamases) and adhesions which can be released into the surrounding medium by commensal and pathogenic strains ([@bib0495], [@bib0015]). Among other roles, these outer membrane vesicles are considered to play a part in biofilm formation ([@bib0490]).

Although various studies have recorded generally mild clinical disease following experimental intra-tracheal inoculation of calves with *P. multocida* ([@bib0210], [@bib0115]), such studies, which circumvent upper respiratory tract defences while challenging animals with a pathogen load which may exceed what is likely in the natural infection, do not provide sufficient evidence of a primary role for *P. multocida* in BRD. Recently, [@bib0530] recorded a decreased risk of treatment for BRD, yet also modestly decreased performance, in calves from which *P. multocida* was detected in the upper respiratory tract. They suggested that these conflicting results might be due to the reliance of *P. multocida* on the presence of other agents or risk factors in BRD pathogenesis. [@bib0030] also found that an association between the isolation of *P. multocida* from tracheobronchial lavage samples from dairy calves in BRD outbreaks in Finland and clinical respiratory disease was not significant when other pathogens were absent. In contrast [@bib0410] identified an association between the presence of *P. multocida* in tracheobronchial lavage fluids and both clinical signs of BRD and raised acute phase proteins, in natural outbreaks among dairy breed calves in dairy herds and fattening units in Finland. They concluded that the association indicated a strong pathogenic role for *P. multocida* in BRD when other recognised pathogens were absent. Such an association does not prove causation and although a significant role for *P. multocida* in BRD appears undeniable, conclusive evidence of a primary role for *P. multocida* is still awaited.

Control of *P. multocida* in Europe is complicated by the absence of a licensed vaccine for cattle. In the US, where vaccination against *P. multocida* has been performed, reports of proven field efficacy are weak or inconsistent ([@bib0440], [@bib0330]). The role of vaccination as a control measure for BRD is discussed further in Part 2 of this review ([@bib0395]). Mass medication of animals with antimicrobials (i.e. metaphylaxis or prophylaxis) is also employed in the control of BRD associated with *P. multocida*. Relevant to this are reports of the prevalence of resistant isolates which also differ between North America and Europe. Although the occurrence of resistant isolates of bacterial pathogens associated with BRD appears to be steadily increasing ([@bib0130]) antimicrobial susceptibility of *P. multocida* for almost all licensed antibiotics for BRD in Europe is very high ([@bib0105]). In the US, a survey of isolates from necropsied animals over an 8 year period from 1994 to 2002 reported a decline in *P. multocida* susceptibility to florfenicol from 100% to 86% in the first 6 years after it came into use ([@bib0560]). [@bib0450] reported a decrease in the numbers of *P. multocida* isolates (from clinically ill and necropsied animals) in US and Canadian diagnostic laboratories which were susceptible to tilmicosin between 2000 and 2009 and a three-fold increase in the MIC~90~ for tulathromycin over a 6 year period from 2004 to 2009. Resistance of *P. multocida* to the aminoglycosides and tetracyclines has been regularly reported ([@bib0105], [@bib0290]). It is interesting to note that ceftiofur, a third generation cephalosporin that is resistant to the β-lactamases produced by *P. multocida*, has maintained its effectiveness since its introduction in 1988 ([@bib0555]). [@bib0300], in publishing the first report on the genetics of macrolide, triamilide and lincosamide resistance in *P. multocida*, observed that the three genes implicated were also present in other bacteria which supported the assumption that *P. multocida* is able to acquire plasmid-borne resistance genes from other gram-negative bacteria.

In conclusion, *P. multocida* is an important pathogen in BRD but its primary role remains unproven. Nevertheless, while assuming an opportunistic role for this pathogen but also recognising its many virulence factors and prevalence in BRD co-infections, the identification of suitable antigen candidates for effective vaccines is still of significant importance if control is to be achieved.

Bovine coronavirus {#s0030}
==================

*Bovine coronavirus* (BCoV) is sometimes shed by healthy cattle ([@bib0100]) but is also associated with three recognised clinical syndromes: calf enteritis, adult winter dysentery and BRD. While studies have identified antigenic and genetic differences between bovine enteric coronaviruses and bovine respiratory coronaviruses ([@bib0235]), all strains belong to a single serotype ([@bib0240]) and there is cross protection between strains ([@bib0075]). BCoV strains appear to be diverging over time from an enteric tropism to a dual enteric and respiratory tropism ([@bib0305], [@bib0435], [@bib0170]).

Seasonal variation in the incidence of respiratory BCoV infections has been reported with peak incidence recorded between November and May in Ireland ([@bib0425]). Stress plays a significant role in the dissemination of infection, with stressors such as the comingling or transport of cattle ([@bib0165]) identified as triggers for viral replication and shedding. Shedding of BCoV can be prolonged, particularly from the faeces, but shedding does not necessarily indicate transmission potential ([@bib0420]). Mortality associated with BRD outbreaks in which BCoV has been identified can be high ([@bib0515], [@bib0125]).

The precise role of BCoV in BRD pathogenesis remains the subject of much debate. [@bib0515], in a study of 26 fatalities (25 of which shed nasal BCoV) and 18 clinically normal controls, which were BCoV isolation-negative, claimed that Evan\'s criteria ([@bib9000]) for causation were satisfied. Published studies since then have supported some of the criteria on which this claim is based -- the virus has been identified at high rates from respiratory secretions and lung samples during the pathogenesis of BRD ([@bib0270], [@bib0425]); animals with high serological titres to BCoV tend to shed BCoV at a lower rate ([@bib0535]) and the primary virus specific immune response to respiratory BCoV is IgM with higher IgG2 responses after the first week of infection while in fatal cases only IgM responses were detected ([@bib0345]). However, their claims that BCoV was not isolated from clinically normal cattle have been contradicted by the findings of [@bib0235] and [@bib0165]. Furthermore, demonstrating that the elimination of the virus factor prevents or decreases the severity of disease has also proved elusive and still awaits the development of an effective vaccine. [@bib0415] in a study of 852 animals on arrival at three feedlots found that higher BCoV arrival titres but not titre changes after arrival reduced BRD risk. They suggested that arrival titres to BRD pathogens could be interpreted as evidence of healthy animals capable of mounting an effective immune response rather than evidence of BCoV-specific protection per se. Furthermore, they argued that if increased weight, in terms of causal inference, was given to exposures that occurred concurrent to, rather than prior to, disease occurrence, the findings of [@bib0515] could be explained by the confounding effect of other pathogens, rather than evidence of causality.

Since the report by [@bib0515], other studies have contributed evidence of a role for BCoV in BRD although the centrality of that role remains somewhat unclear. In a study of 837 calves from four feedlots, [@bib0335] reported that animals that shed BCoV were at increased odds of pulmonary lesions (OR 2.2, 95% CI 1.12--4.32) and that seroconversion to BCoV during the first 28 days was associated with reduced odds (0.59; 0.42--0.84) of treatmentfor BRD but only in those animals that did not shed BCoV. [@bib0445], in a randomised trial with 414 heifers, examined the effect of intranasal modified live BCoV vaccination, nasal BCoV shedding and BCoV serological titres on entry to the feedlot on the risk of treatment for BRD. Intranasal vaccination was found to be protective (*P* = 0.008) and nasal shedding of BCoV increased BRD treatment risk (*P* = 0.009).

Results from natural outbreaks have also supported a role for BCoV in BRD pathogenesis. [@bib0270] detected BCoV by reverse transcriptase quantitative PCR (RT-qPCR) in 9-month-old weanlings presenting with BRD in a paddock-based feedlot system; BCoV was identified in nasal samples from 10/30 acutely affected animals and in the lungs of 2/15 with BRD lesions at slaughter. Other viruses were not detected in these animals and bronchointerstitial pneumonia was diagnosed on histopathology. [@bib0125] reported on four outbreaks involving young calves, both dairy and beef breeds, aged 2--3 months in Italy. BCoV was detected by RT-PCR on a high proportion of nasal swabs from all four outbreaks; no other BRD virus or *Mycoplasma* spp. was identified in three of the four outbreaks. In two of these outbreaks concurrent respiratory and enteric signs were recorded with nasal and faecal detection of BCoV.

On balance, epidemiological evidence of BCoV induced BRD is persuasive, however, studies demonstrating BCoV antigen in pneumonic lesions are lacking and would provide more conclusive evidence. [@bib0435] demonstrated BCoV antigen in the cytoplasm of degenerated and necrotic epithelial cells of the nasal turbinates, trachea and lungs with concurrent interstitial pneumonia using immunohistochemistry (IHC) in calves experimentally infected orally with a winter dysentery strain of BCoV; respiratory clinical signs were not recorded however. Histological changes including multinucleate syncytial epithelial cells identified in the bronchiolar lumina and bronchus associated lymphoid tissue (BALT) hyperplasia have been ascribed to BCoV in a natural outbreak by [@bib0270] based on PCR rather than IHC detection.

Control of the disease is challenging as respiratory BCoV vaccines have not been developed and while [@bib0445] reported that intranasal use of modified live BCoV vaccine reduced the risk of treatment for BRD in calves, differences between the strain used in the enteric BCoV vaccine and those strains isolated from BRD cases suggest that the vaccine may not be fully protective against the BCoV isolates in circulation ([@bib0170]). [@bib0445] assumed that the effect of vaccination was mediated by IgA but further research is required to confirm the factors which confer mucosal protection. Considering the apparent changing tropism of BCoV strains ([@bib0305]) coupled with BCoV transmission by either the nasal or faecal-oral route and considering that experimental oral infection can lead to viral infection of respiratory epithelial cells ([@bib0435]) it is likely that any effective vaccine will need to confer concurrent enteric and nasal mucosal immunity. Control is further complicated by the potential for re-infection of the same animal and persistence of infection in both the upper respiratory tract ([@bib0260]) and in intestinal tissues and lymph nodes ([@bib0420]) of infected animals possibly for weeks after infection.

Bovine adenovirus 3 {#s0035}
===================

Bovine adenoviruses (BAdV) were first identified by [@bib0310] in the faeces of a healthy cow. Since then, 10 serotypes have been identified in cattle which are distributed between two subgroups -- the *Mastadenoviruses* and the *Atadenoviruses* ([@bib0045]). Although BAdV-10 is unlike other BAdV species, it displays certain characteristics of *Mastadenoviruses* ([@bib0355]). BAdVs appear to have both respiratory and enteric tropisms ([@bib0360], [@bib0460]) but many serotypes are of uncertain significance as pathogens ([@bib0505]). Shedding of multiple BAdV genotypes by cattle is prevalent such that, considering the environmental stability of the AdV virion, BAdVs have been suggested as conservative indicators of the presence of viral or faecal contamination in aqueous environments ([@bib0505]).

Transmission of BAdV-3 is facilitated by enhanced survival in aerosols in conditions of low temperatures and high relative humidity ([@bib0145]) and within infected herds seropositivity to BAdV-3 is often high ([@bib0365], [@bib0505]). Indeed, the apparent low incidence of clinical disease, coupled with the ability of BAdV-3 to infect both dividing and non-dividing cells and to induce both humoral and cell mediated immunity, has led to a focus on the potential use of BAdV-3, with genetic modification of capsid proteins, as a vaccine delivery vehicle in cattle and other animals ([@bib0035]).

The pathogenic significance of BAdV-3 remains uncertain. In a study of feedlot calves during the first 56 days on feed, [@bib0365] reported an association between BAdV-3 natural infection and seroconversion with pyrexia, but not with weight gain. [@bib0405], using viral metagenomics on nasopharyngeal swabs taken from 100 dairy calves aged between 4 and 8 weeks in a BRD case--control study, showed that the detection of BAdV-3 was significantly (*P *\<* *0.0001) associated with BRD. In Turkey, [@bib0065], using direct fluorescent antibody technique and immunoperoxidase staining of pneumonic lungs from 247 cattle identified with lung lesions at slaughter, recorded BAdV3 antigen specific staining in infiltrating peribronchiolar mononuclear cells and in bronchiolar and alveolar epithelial cells generally in the pneumonic areas of the lung. No immunopositive or fluorescence staining was detected in the negative controls. Degeneration of bronchial and bronchiolar epithelium and mononuclear cell infiltration have been recorded as consistent histological features in these diseased lungs.

The apparent subclinical infection of some animals coupled with the sometimes severe pathological changes observed in others has led to uncertainty regarding the co-factors responsible for BAdV-associated BRD in cattle. Immunological or genetic factors may be implicated in the progression of disease. Based on experimental inoculation, differences in immune system development (i.e. development of cell-mediated immunity) between neonatal and older calves appear to strongly influence immunopathological reactions to BAV-3 ([@bib0400], [@bib0570]).

In summary, recent studies have added weight to claims of a role for BAdV-3 in some BRD outbreaks but further investigation of the potential immunological or genetic factors that influence the development or severity of disease is warranted.

Influenza D virus {#s0040}
=================

[@bib0245] described an influenza virus isolated from swine in 2011 with moderate homology to Influenza C virus which was provisionally designated Influenza D virus (IDV; [@bib0250]). IDV is a single strand, negative sense RNA virus belonging to the family *Orthomyxoviridae*. Since 2011, IDV has been identified in many countries ([@bib0245], [@bib0295], [@bib0070]) with a homology between strains which suggests that IDV has a global distribution ([@bib0080]). Cattle have been proposed as the natural host of the virus ([@bib0160]) while evidence of infection has been detected in other species, including humans ([@bib0245], [@bib0455], [@bib0565]). Studies of transmission dynamics of IDV have shown that IDV can be transmitted efficiently between cattle by direct contact ([@bib0160]). IDV appears to be present in cattle populations for some time and the seroprevalence of IDV in cattle is relatively high with 15.9% prevalence reported by [@bib0155] in a retrospective survey (2004--2006) of 6--8 month old calves and cows in the US. They also showed that antigenically distinct clusters of IDV may be detected co-circulating in cattle populations at the same time.

[@bib0080] proposed a primary role for IDV in BRD pathogenesis based on five of 10 IDV quantitative real-time PCR (qRT-PCR) positive clinical BRD samples (swabs or lung tissue) having no other BRD virus detected; however, bacteriology was not reported in this study nor were control animals used for comparison. [@bib0155] recorded nasal or nasopharyngeal swab prevalence by qRT-PCR of 29.1% among sick and 2.4% among healthy 6--9 month old beef calves but acknowledged that the contribution of IDV to the BRD recorded was unknown. [@bib0160] recorded only mild disease associated with experimental infection of 4 month old male dairy calves. They suggested that their findings, together with those of [@bib0405], which identified IDV at a high prevalence (14%) using viral metagenomics in 4--8 week old dairy calves with BRD but not in 50 healthy controls, supported a facilitator role rather than a primary role for IDV in BRD. In the lungs, they detected IDV nucleic acid by qRT-PCR but not IDV antigen using IHC which was suggestive of IDV causing an upper respiratory tract infection.

In conclusion, research into IDV pathogenesis and its role in BRD continues. Early indications suggest a relatively prevalent virus in cattle populations which is unlikely to play a primary role in BRD outbreaks but which may facilitate disease caused by other BRD pathogens.

Bovine rhinitis A virus {#s0045}
=======================

Bovine rhinitis A virus (BRAV), a single-stranded positive-sense RNA virus, is a species of the genus Aphthovirus in the family *Picornaviridae*. Two serotypes have been identified -- BRAV 1 and BRAV 2.

Although BRAV was first identified in 1962, relatively little is known about its role in BRD pathogenesis ([@bib0255]). [@bib0280] recorded mild respiratory disease following the experimental inoculation of 6--8 week old dairy bull calves by multiple routes with the virus. Isolation of the virus from healthy animals has also been recorded ([@bib0380]), however, [@bib0405] reported a significant association between the detection of BRAV in nasal secretions of dairy calves and BRD; a nasal prevalence of 30% was recorded while recognised BRD viruses were not detected. [@bib0255] recorded bovine rhinitis virus \[either BRAV or bovine rhinitis B virus (BRBV)\] in 6.4% of nasopharyngeal or lung samples from BRD cases and through metagenomic sequencing of a subset of these showed that co-infections with multiple serotypes of bovine rhinitis are common in cattle. Seroprevalence studies, though few, have recorded high prevalence of antibodies to BRAV among cattle ([@bib0380]).

Much work remains in determining the significance of these findings. [@bib0255] readily acknowledged that further research is needed to determine if bovine rhinitis viruses are pathogenic or commensal viruses.

Conclusions {#s0050}
===========

In light of evolving knowledge regarding the role of specific pathogens in BRD pathogenesis we need to regularly reappraise our understanding of BRD pathogenesis and control. Emerging knowledge of pathogens traditionally assumed to play minor roles in BRD shows us that the 'playing field' for BRD is more crowded than previously thought and that the potential role of these pathogens, either alone or in concert with other BRD pathogen infections, should not be discounted.
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